BGM Group Ltd. BGM PHARMA
Company Overview
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.29.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $37.92M (+51.1% YoY); net profit $-19.94M.
- Trailing 12 Months Year-on-year growth — revenue +69.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -16.4%, profit CAGR -650.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -16.38% |
| 1 Year: | 69.80% |
Compounded Profit Growth
| 5 Years: | -650.69% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -96.13% |
| 6 Months: | -70.75% |
| 3 Months: | -9.22% |
| 1 Month: | -3.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)51.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -16.4% CAGR over 5 years.
- Earnings shrank at -650.7% CAGR over 5 years.
- Trading 97.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BGM BGM Group Ltd. PHARMA | 0.29 | -1.81 | $110.38M | 0.00% | -3.17% | -7.41% | -16.38% | -650.69% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 64.86M | 46.47M | 25.10M | 37.92M |
| Cost of Revenue | - | 58.63M | 44.72M | 20.98M | 31.61M |
| Gross Profit | - | 6.23M | 1.75M | 4.11M | 6.31M |
| Operating Expenses | - | 3.71M | 4.17M | 4.47M | 18.76M |
| Operating Income | - | 2.52M | -2.42M | -357.36K | -12.45M |
| EBITDA | - | 3.74M | -1.27M | 879.87K | -10.99M |
| Interest Expense | 57.67K | - | - | - | - |
| Pretax Income | - | 1.56M | -7.90M | -2.14M | -19.94M |
| Tax Provision | - | 194.30K | 219.17K | -619.98K | 277.79K |
| Net Income | - | 1.08M | -7.78M | -1.44M | -19.94M |
| Diluted EPS | - | 0.15 | -1.08 | -0.20 | -0.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 64.53M | 51.26M | 53.00M | 433.81M |
| Current Assets | - | 30.03M | 34.51M | 29.77M | 51.55M |
| Cash & Equivalents | - | 14.32M | 7.48M | 9.82M | 9.82M |
| Inventory | - | 8.88M | 4.99M | 5.05M | 20.10M |
| Receivables | - | 815.33K | 1.98M | 1.54M | 4.25M |
| Total Liabilities | - | 9.56M | 6.91M | 8.91M | 41.92M |
| Current Liabilities | - | 9.18M | 6.66M | 8.78M | 41.60M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.77M | 577.85K | 0 | 1.94M |
| Total Equity | - | 53.05M | 42.79M | 42.74M | 390.88M |
| Shares Outstanding | - | 7.15M | 7.15M | 7.23M | 200.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 12.65M | 312.21K | 544.24K | -2.37M |
| Investing Cash Flow | - | -3.26M | -4.74M | 983.42K | -162.91K |
| Financing Cash Flow | - | -5.94M | -2.92M | -491.73K | 2.62M |
| Capital Expenditure | - | -3.26M | -3.71M | -3.93M | -2.19M |
| Free Cash Flow | - | 9.40M | -3.40M | -3.39M | -4.56M |
| Net Change in Cash | - | 3.46M | -7.35M | 1.04M | 83.58K |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 9.6% | 3.8% | 16.4% | 16.6% |
| Operating Margin % | - | 3.9% | -5.2% | -1.4% | -32.8% |
| Net Margin % | - | 1.7% | -16.7% | -5.7% | -52.6% |
| ROE % | - | 2.0% | -18.2% | -3.4% | -5.1% |
| ROCE % | - | 4.5% | -5.4% | -0.8% | -3.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.28% | 98.47K | $24.72K |
| 2 | Xtx Topco Ltd | 0.18% | 63.09K | $15.84K |
| 3 | UBS Group AG | 0.16% | 57.65K | $14.47K |
| 4 | Jane Street Group, LLC | 0.16% | 57.23K | $14.36K |
| 5 | Virtu Financial LLC | 0.15% | 54.21K | $13.61K |
| 6 | Susquehanna International Group, LLP | 0.09% | 32.07K | $8.05K |
| 7 | Ground Swell Capital, LLC | 0.03% | 11.10K | $2.79K |
| 8 | JPMORGAN CHASE & CO | 0.01% | 1.81K | $455 |
| 9 | Royal Bank of Canada | - | 1.50K | $376 |
| 10 | Morgan Stanley | - | 200 | $50 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BGM
BGM Group (NASDAQ: BGM) set to lift share count to 380M - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNUjFwcDc3ZXdPR1VkOUJyOUotNVo3azFLRGFuNm5WdG1yTHBiZ1F2NnVaellzSW5VeVRPTVVsUU1nalRZQUlLNkM3b2F0QlFWV1hHa0h5dUctNVVqY3lwcF9jTzF1VXZZWDh0SUVnblBWQ1g0TUdHMnR2RVRzdnk0bVJSXzRqcURTM1hpMn…
BGM Group (BGM) Stock Faces EPS Swing To Loss Challenges Bullish Growth Narratives - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQekhWUkVPek16SHpmWEI2Q3NwcExhUkZCb2FkT0JzYk01aG9ncnVBWVhHbmFqMXFNU1NYcUg4ZDh2NVpKMGhtdXRjQjNkUTMtdGpEdHg5M05ONEJKaUdEeTlmTFg0ZmtRUWs0VWFucFpEeHNsWVZUVnExRThKS1o4YWRzQi1rQUdWTDZPRn…
BGM Group Ltd. (BGM) Stock Analysis: Navigating Volatility in the Chinese Pharmaceutical Sector - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNjF3SnBZTlMzVlBWcldhNC0xWUhlM1kyb3ZibWFhT1NtWmxyNk1vYzFQR2lETEJJTkRQWFhRek96U29seUdBRERtWDZxT244VFFRNk5UQTJSNThKOGdCa0RFQy00NWtzcVNHTnRUcFE0a1pPTW9HLWVqYXc1MDQwZ1drSWRDVUlPV25rbF…
Best Chinese Stocks To Keep An Eye On - August 17th - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQYXFvZm1xamxaLWFuLVlnU2NGX09ZSGVFRkNBVnIxSjVSQ3l1YTdqVFI2bGc5ek9VSWszbi1RaTg2aUkxWmF4Z0VtQWE4Zlo5aksyU29CMFRQc3ZrVUZuU2FtYjNfVU1FWTFvY2c4NkRKNGtldWs1VUFKS29qVUxFMWkxNktYZXFIejhOam…
BGM Group (BGM) reshapes leadership as Chen Xin resigns top roles - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOMHBnTmt2ZmppTW5kOVd4WGJha19Va1BxT1RnalpDQlZXZ0FkS1lMLTh3MXVhWXRBZVA1ckx1ZlJqODhCd3pzUGo1LUZCU2IzQ2lHeGlFM1pYNXZFeEhNMWdMTm5mNmpTUmxjT1BvQ1M1VXFXdUhZWGRkazZ5dFpfTEVVM2lZNjZ5MXhDbF…
BGM (BGM) Closing Note: Finishes 6.08% Up at $0.29 on the Day; Boundary Check: the Supplied Trading Band Runs From $0.28 to $0.30 in the Latest Session - Safe Entry Stocks - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxNUGFwdEhUbE1kR3FVMTBxNzNvZmtYUjk3d2ZBLWNjeDNTYzZhZW1yU2pqS2VBZEd2Qld1T2lYNkxJQm1LRkZYTG51WWUzbjdGQ0Z1Ul9UQVdoeUxCbWpUX3hmSlpKUWZ4SDJCSHFwdmYxUHBmSWJBQVJCWU5lY1lXQ0IwR2phdTBYZUdENG…
BGM — Frequently Asked Questions
What is the current share price of BGM Group Ltd. (BGM)?
As of 2026-09-19 21:16 PDT, BGM Group Ltd. (BGM) trades at $0.29 on NasdaqCM. Its 52-week range is $0.25 to $11.75.
What is the market capitalisation of BGM?
BGM Group Ltd. (BGM) has a market capitalisation of $110.38M on NasdaqCM.
What is the P/E ratio of BGM?
BGM trades at a trailing price-to-earnings (P/E) ratio of -1.81. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.13.
What is the return on equity (ROE) of BGM?
BGM has a return on equity (ROE) of -7.41%. Its return on capital employed (ROCE) is -3.17%.
Is BGM a good stock to buy?
This page provides a data-driven analysis of BGM Group Ltd. (BGM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.